{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:39:38Z","timestamp":1761871178558,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470296","31701198"],"award-info":[{"award-number":["81470296","31701198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20170386"],"award-info":[{"award-number":["BK20170386"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clml.2018.11.006","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T19:43:12Z","timestamp":1542051792000},"page":"e107-e115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Role of FLT3-ITD Mutation on de Novo MDS in Chinese Population"],"prefix":"10.1016","volume":"19","author":[{"given":"Fei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ling","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Qiu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Ning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-Pei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Bai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4127-5054","authenticated-orcid":false,"given":"Qiao-Cheng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Li","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.11.006_bib1","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2010-04-279794","volume":"116","author":"Miesner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.006_bib2","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3324\/haematol.10869","article-title":"A\u00a0comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia","volume":"92","author":"Bacher","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.006_bib3","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/leu.2010.124","article-title":"Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML","volume":"24","author":"Dicker","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.11.006_bib4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/leu.2010.304","article-title":"An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling","volume":"25","author":"Flach","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.11.006_bib5","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/leu.2013.165","article-title":"Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML","volume":"27","author":"Takahashi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.11.006_bib6","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.leukres.2015.10.005","article-title":"Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.11.006_bib7","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.3324\/haematol.2015.127985","article-title":"Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia","volume":"100","author":"Meggendorfer","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.11.006_bib8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2141.2008.07245.x","article-title":"Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review","volume":"142","author":"Bernasconi","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.11.006_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.11.006_bib10","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ajh.24901","article-title":"Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.11.006_bib11","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.006_bib12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2018.11.006_bib13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1182\/blood-2015-11-683334","article-title":"Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies","volume":"128","author":"McKerrell","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.006_bib14","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.006_bib15","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.006_bib16","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","article-title":"Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Bejar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.11.006_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2018.11.006_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/10245332.2017.1372248","article-title":"The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients","volume":"23","author":"Qiu","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2018.11.006_bib19","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.11.006_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.23345","article-title":"FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Daver","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.11.006_bib21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/ijms17040440","article-title":"Molecular and cellular mechanisms of myelodysplastic syndrome: implications on targeted therapy","volume":"17","author":"Gill","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2018.11.006_bib22","doi-asserted-by":"crossref","first-page":"27882","DOI":"10.18632\/oncotarget.25328","article-title":"Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature","volume":"9","author":"Kuendgen","year":"2018","journal-title":"Oncotarget"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:26Z","timestamp":1761870686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018311194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2152265018311194"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.11.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of FLT3-ITD Mutation on de Novo MDS in Chinese Population","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}